New Zealand Medicines and Medical Devices Safety Authority (Medsafe) Considerations for First-In-Human (FIH) and Early Phase Clinical Trials (Catapult’s regulatory round-up – September 2024)
2. |
Considerations for First-In-Human (FIH) and Early Phase Clinical Trials |
End Date: 27 October 2024 |
Stakeholder Consultation |
Text published on the 1st of October 2024 in Catapult’s Regulatory Round-up – September 2024 (catapult.org.uk).
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (19 novembre 2024). New Zealand Medicines and Medical Devices Safety Authority (Medsafe) Considerations for First-In-Human (FIH) and Early Phase Clinical Trials (Catapult’s regulatory round-up – September 2024). ELSIBI. Consulté le 18 mars 2025 à l’adresse https://doi.org/10.58079/12ps2